342 related articles for article (PubMed ID: 9795171)
1. Methamphetamine induces fos expression in the striatum and the substantia nigra pars reticulata in a rat model of Parkinson's disease.
Ishida Y; Todaka K; Kuwahara I; Ishizuka Y; Hashiguchi H; Nishimori T; Mitsuyama Y
Brain Res; 1998 Oct; 809(1):107-14. PubMed ID: 9795171
[TBL] [Abstract][Full Text] [Related]
2. Methamphetamine-induced Fos expression in the substantia nigra pars reticulata in rats with a unilateral 6-OHDA lesion of the nigrostriatal fibers.
Ishida Y; Todaka K; Kuwahara I; Nakane H; Ishizuka Y; Nishimori T; Mitsuyama Y
Neurosci Res; 1998 Apr; 30(4):355-60. PubMed ID: 9678640
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic transplants suppress L-DOPA-induced Fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Ishida Y; Kuwahara I; Todaka K; Hashiguchi H; Nishimori T; Mitsuyama Y
Brain Res; 1996 Jul; 727(1-2):205-11. PubMed ID: 8842399
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D1- and D2-dependent catalepsy in the rat requires functional NMDA receptors in the corpus striatum, nucleus accumbens and substantia nigra pars reticulata.
Ozer H; Ekinci AC; Starr MS
Brain Res; 1997 Nov; 777(1-2):51-9. PubMed ID: 9449412
[TBL] [Abstract][Full Text] [Related]
5. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease.
Paul ML; Graybiel AM; David JC; Robertson HA
J Neurosci; 1992 Oct; 12(10):3729-42. PubMed ID: 1357113
[TBL] [Abstract][Full Text] [Related]
6. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
Engber TM; Anderson JJ; Boldry RC; Kuo S; Chase TN
Neuroscience; 1993 Jun; 54(4):1051-61. PubMed ID: 8101981
[TBL] [Abstract][Full Text] [Related]
7. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
8. Time dependence and role of N-methyl-D-aspartate glutamate receptors in the priming of D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats.
Pollack AE; Strauss JB
Brain Res; 1999 May; 827(1-2):160-8. PubMed ID: 10320705
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of Fos and Zif268 in the nigrostriatal system after methamphetamine administration in a rat model of Parkinson's disease.
Ishida Y; Kawai K; Magata Y; Ebihara K; Takeda R; Abe H; Yoshimoto M; Hashiguchi H; Odagiri K; Matsuo H; Nishimori T
Synapse; 2008 Dec; 62(12):920-6. PubMed ID: 18792992
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
Bordet R; Ridray S; Schwartz JC; Sokoloff P
Eur J Neurosci; 2000 Jun; 12(6):2117-23. PubMed ID: 10886351
[TBL] [Abstract][Full Text] [Related]
11. N-methyl-D-aspartate receptor blockade attenuates D1 dopamine receptor modulation of neuronal activity in rat substantia nigra.
Huang KX; Bergstrom DA; Ruskin DN; Walters JR
Synapse; 1998 Sep; 30(1):18-29. PubMed ID: 9704877
[TBL] [Abstract][Full Text] [Related]
12. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host.
Bentlage C; Nikkhah G; Cunningham MG; Björklund A
Exp Neurol; 1999 Sep; 159(1):177-90. PubMed ID: 10486186
[TBL] [Abstract][Full Text] [Related]
13. Systemic morphine-induced Fos protein in the rat striatum and nucleus accumbens is regulated by mu opioid receptors in the substantia nigra and ventral tegmental area.
Bontempi B; Sharp FR
J Neurosci; 1997 Nov; 17(21):8596-612. PubMed ID: 9334431
[TBL] [Abstract][Full Text] [Related]
14. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
15. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
[TBL] [Abstract][Full Text] [Related]
16. Cortical stimulation induces Fos expression in striatal neurons via NMDA glutamate and dopamine receptors.
Liste I; Rozas G; Guerra MJ; Labandeira-Garcia JL
Brain Res; 1995 Nov; 700(1-2):1-12. PubMed ID: 8624698
[TBL] [Abstract][Full Text] [Related]
17. Dopamine D2 receptor control of pallidal fos expression: comparisons between intact and 6-hydroxydopamine-treated hemispheres.
Marshall JF; Cole BN; LaHoste GJ
Brain Res; 1993 Dec; 632(1-2):308-13. PubMed ID: 7908600
[TBL] [Abstract][Full Text] [Related]
18. The corticostriatal system mediates the "paradoxical" contraversive rotation but not the striatal hyperexpression of Fos induced by amphetamine early after 6-hydroxydopamine lesion of the nigrostriatal pathway.
Lopez-Martin E; Rozas G; Rodriguez J; Guerra MJ; Labandeira-Garcia JL
Exp Brain Res; 1998 May; 120(2):153-63. PubMed ID: 9629957
[TBL] [Abstract][Full Text] [Related]
19. Roles of dopamine D1 receptors in striatal fos protein induction associated with methamphetamine behavioral sensitization in rats.
Yoshida H; Ohno M; Watanabe S
Brain Res Bull; 1995; 38(4):393-7. PubMed ID: 8535862
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal dopamine-rich implants reverse the changes in dopamine D2 receptor densities caused by 6-hydroxydopamine lesion of the nigrostriatal pathway in rats: an autoradiographic study.
Savasta M; Mennicken F; Chritin M; Abrous DN; Feuerstein C; Le Moal M; Herman JP
Neuroscience; 1992; 46(3):729-38. PubMed ID: 1532053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
